November 4th 2024
The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed following treatment with a type I JAK2 inhibitor.
September 30th 2024
Challenges of Interpreting JAK Inhibitor Data for Real-World Myelofibrosis Care
March 4th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.
Read More
Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis
February 8th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed JAK inhibitor options and the data from the PERSIST-2 trial of pacritinib. This is the first of 2 articles based on this event.
Read More
Transfusion Independence With Momelotinib Impacts OS in Myelofibrosis
January 11th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.
Read More
Momelotinib Addresses Anemia in Myelofibrosis
January 7th 2024Findings from the MOMENTUM study evaluating momelotinib demonstrated symptom, spleen, and anemia benefits in myelofibrosis compared with danazol in previously treated patients with anemia and intermediate- or high-risk myelofibrosis.
Read More
AI Tool Accurately Differentiates MPNs Using Bone Marrow Biopsies
December 28th 2023Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.
Read More
Management of Ruxolitinib in MF Allows for Continued Survival Benefit
December 28th 2023In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.
Read More
Importance of Early Start to Therapy and SCT Referral in Myelofibrosis
December 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.
Read More
Pelabresib/Ruxolitinib Combo Betters Splenomegaly, TSS in JAK Inhibitor-Naive MF
December 11th 2023Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor-naive myelofibrosis.
Read More
Utilizing Interpretable AI to Distinguish prePMF From ET
December 10th 2023Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Watch
ACVR1 Inhibition With Pacritinib Leads to Anemia Improvement in MF
November 29th 2023Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.
Read More
Oh Discusses Goals of Treatment in Patients With Cytopenic Myelofibrosis
November 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen T. Oh, MD, PhD, discussed with participants when they would use pacritinib for patients with thrombocytopenia related to myelofibrosis.
Read More
Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF
November 21st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Read More
MANIFEST-2 Meets Primary End Point With Pelabresib Plus Ruxolitinib in MF
November 21st 2023Along with improvements shown for the primary and secondary end points of the phase 3 MANIFEST-2 trial in JAK inhibitor-naive patients with myelofibrosis, pelabresib plus ruxolitinib did not display any new safety signals.
Read More